|
1
|
Hofbauer LC, Hamann C and Ebeling PR:
Approach to the patient with secondary osteoporosis. Eur J
Endocrinol. 162:1009–1020. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rizzoli R and Biver E:
Glucocorticoid-induced osteoporosis: Who to treat with what agent?
Nat Rev Rheumatol. 11:98–109. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Canalis E, Mazziotti G, Giustina A and
Bilezikian JP: Glucocorticoid-induced osteoporosis: Pathophysiology
and therapy. Osteoporos Int. 18:1319–1328. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
O'Brien CA, Jia D, Plotkin LI, Bellido T,
Powers CC, Stewart SA, Manolagas SC and Weinstein RS:
Glucocorticoids act directly on osteoblasts and osteocytes to
induce their apoptosis and reduce bone formation and strength.
Endocrinology. 145:1835–1841. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jia D, O'Brien CA, Stewart SA, Manolagas
SC and Weinstein RS: Glucocorticoids act directly on osteoclasts to
increase their life span and reduce bone density. Endocrinology.
147:5592–5599. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Harada S and Rodan GA: Control of
osteoblast function and regulation of bone mass. Nature.
423:349–355. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karsenty G and Wagner EF: Reaching a
genetic and molecular understanding of skeletal development. Dev
Cell. 2:389–406. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ash P, Loutit JF and Townsend KM:
Osteoclasts derived from haematopoietic stem cells. Nature.
283:669–670. 1980. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lacey DL, Timms E, Tan HL, Kelley MJ,
Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S,
et al: Osteoprotegerin ligand is a cytokine that regulates
osteoclast differentiation and activation. Cell. 93:165–176. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lagasse E and Weissman IL: Enforced
expression of Bcl-2 in monocytes rescues macrophages and partially
reverses osteopetrosis in op/op mice. Cell. 89:1021–1031. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bonyadi M, Waldman SD, Liu D, Aubin JE,
Grynpas MD and Stanford WL: Mesenchymal progenitor self-renewal
deficiency leads to age-dependent osteoporosis in Sca-1/Ly-6A null
mice. Proc Natl Acad Sci USA. 100:pp. 5840–5845. 2003; View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miura M, Chen XD, Allen MR, Bi Y, Gronthos
S, Seo BM, Lakhani S, Flavell RA, Feng XH, Robey PG, et al: A
crucial role of caspase-3 in osteogenic differentiation of bone
marrow stromal stem cells. J Clin Invest. 114:1704–1713. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen TL: Inhibition of growth and
differentiation of osteoprogenitors in mouse bone marrow stromal
cell cultures by increased donor age and glucocorticoid treatment.
Bone. 35:83–95. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang Q, Shi J, Gao B, Zhang HY, Fan J, Li
XJ, Fan JZ, Han YH, Zhang JK, Yang L, et al: Gastrodin: An ancient
Chinese herbal medicine as a source for anti-osteoporosis agents
via reducing reactive oxygen species. Bone. 73:132–144. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Boyce BF: Advances in osteoclast biology
reveal potential new drug targets and new roles for osteoclasts. J
Bone Miner Res. 28:711–722. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang K, Niu J, Kim H and Kolattukudy PE:
Osteoclast precursor differentiation by MCPIP via oxidative stress,
endoplasmic reticulum stress, and autophagy. J Mol Cell Biol.
3:360–368. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiu Y, Xu H, Zhao C, Li J, Morita Y, Yao
Z, Xing L and Boyce BF: Chloroquine reduces osteoclastogenesis in
murine osteoporosis by preventing TRAF3 degradation. J Clin Invest.
124:297–310. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shi J, Wang L, Zhang H, Jie Q, Li X, Shi
Q, Huang Q, Gao B, Han Y, Guo K, et al: Glucocorticoids:
Dose-related effects on osteoclast formation and function via
reactive oxygen species and autophagy. Bone. 79:222–232. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen L, Wei X, Hou Y, Liu X, Li S, Sun B,
Liu X and Liu H: Tetramethylpyrazine analogue CXC195 protects
against cerebral ischemia/reperfusion-induced apoptosis through
PI3K/Akt/GSK3β pathway in rats. Neurochem Int. 66:27–32. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gong X, Ivanov VN, Davidson MM and Hei TK:
Tetramethylpyrazine (TMP) protects against sodium arsenite-induced
nephrotoxicity by suppressing ROS production, mitochondrial
dysfunction, pro-inflammatory signaling pathways and programed cell
death. Arch Toxicol. 89:1057–1070. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu N, Zhang Z, Chen P, Zhong Y, Cai X, Hu
H, Yang Y, Zhang J, Li K, Ge J, et al: Tetramethylpyrazine (TMP),
an active ingredient of Chinese herb medicine Chuanxiong,
attenuates the degeneration of trabecular meshwork through
SDF-1/CXCR4 axis. PLoS One. 10:e01330552015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang L, Zhang HY, Gao B, Shi J, Huang Q,
Han YH, Hu YQ, Lu WG, Zhao ZJ, Liu BH, et al: Tetramethylpyrazine
protects against glucocorticoid-induced apoptosis by promoting
autophagy in mesenchymal stem cells and improves bone mass in
glucocorticoid-induced osteoporosis rats. Stem Cells Dev.
26:419–430. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lu C, Zhang J, Shi X, Miao S, Bi L, Zhang
S, Yang Q, Zhou X, Zhang M, Xie Y, et al: Neuroprotective effects
of tetramethylpyrazine against dopaminergic neuron injury in a rat
model of Parkinson's disease induced by MPTP. Int J Biol Sci.
10:350–357. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bouffi C, Bony C, Courties G, Jorgensen C
and Noël D: IL-6-dependent PGE2 secretion by mesenchymal stem cells
inhibits local inflammation in experimental arthritis. PLoS One.
5:e142472010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dominici M, Le Blanc K, Mueller I,
Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A,
Prockop Dj and Horwitz E: Minimal criteria for defining multipotent
mesenchymal stromal cells. The International society for cellular
therapy position statement. Cytotherapy. 8:315–317. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang X, Harimoto K, Liu J, Guo J, Hinshaw
S, Chang Z and Wang Z: Spata4 promotes osteoblast differentiation
through Erk-activated Runx2 pathway. J Bone Miner Res.
26:1964–1973. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen JJ, Zhang NF, Mao GX, He XB, Zhan YC,
Deng HB, Song DQ, Li DD, Li ZR, Si SY, et al: Salidroside
stimulates osteoblast differentiation through BMP signaling
pathway. Food Chem Toxicol. 62:499–505. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang L, Fan J, Lin YS, Guo YS, Gao B, Shi
QY, Wei BY, Chen L, Yang L, Liu J and Luo ZJ: Glucocorticoids
induce autophagy in rat bone marrow mesenchymal stem cells. Mol Med
Rep. 11:2711–2716. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cui L, Li T, Liu Y, Zhou L, Li P, Xu B,
Huang L, Chen Y, Liu Y, Tian X, et al: Salvianolic acid B prevents
bone loss in prednisone-treated rats through stimulation of
osteogenesis and bone marrow angiogenesis. PLoS One. 7:e346472012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu J, Cao Y, Wu T, Li D and Lu H: Micro-CT
as a tool to investigate the efficacy of tetramethylpyrazine in a
rat spinal cord injury model. Spine (Phila Pa 1976). 41:1272–1278.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gao B, Huang Q, Jie Q, Zhang HY, Wang L,
Guo YS, Sun Z, Wei BY, Han YH, Liu J, et al: Ginsenoside-Rb2
inhibits dexamethasone-induced apoptosis through promotion of
GPR120 induction in bone marrow-derived mesenchymal stem cells.
Stem Cells Dev. 24:781–790. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim HJ, Zhao H, Kitaura H, Bhattacharyya
S, Brewer JA, Muglia LJ, Ross FP and Teitelbaum SL: Glucocorticoids
suppress bone formation via the osteoclast. J Clin Invest.
116:2152–2160. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Papanicolaou DA and Vgontzas AN:
Interleukin-6: The endocrine cytokine. J Clin Endocrinol Metab.
85:1331–1333. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tanaka Y: Glucocorticoid and bone
metabolism and disease. Clin Calcium. 23:229–235. 2013.(In
Japanese). PubMed/NCBI
|
